Might be too soon to tell impact on oropharyngeal and anal cancers<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, March 16, 2022 (HealthDay News) — The recent decrease in the incidence of cervical cancers, particularly in young women, may be associated with human papillomavirus (HPV) vaccination approval, according to a study published online March 16 in JAMA Network Open<\/em>.<\/p>\n Cheng-I Liao, M.D., from the Kaohsiung Veterans General Hospital in Taiwan, and colleagues examined the association between vaccination availability and the incidence of HPV-attributable cancers. Analysis included cancer data from the U.S. Cancer Statistics Public Use Database (2001 through 2017) and HPV vaccination and screening data from two national databases.<\/p>\n The researchers found that before vaccination approval, cervical cancer rates in the 20- to 24-year age group were decreasing at 2.29 percent annually; since approval, the rate has been decreasing by 9.50 percent. Annual increases for oropharyngeal (2.71 percent) and anal\/rectal (1.83 percent) cancers were seen for men. Among women, the incidence of oropharyngeal cancer remained stable but anal\/rectal cancer increased at 2.83 percent every year.<\/p>\n “These findings suggest that the decrease in the incidence of cervical cancers, particularly in young women, may be associated with HPV vaccination approval; however, it may be too early to evaluate this association in oropharyngeal and anal cancers, which occur later in life,” the authors write.<\/p>\n One author disclosed financial ties to the pharmaceutical industry.<\/p>\n